Navigation Links
OvaGene Oncology Joins The Gynecologic Oncology Group (GOG) Industry Collaboration Team to Advance Gynecologic Cancer Research

IRVINE, Calif., Aug. 4 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, is pleased to announce their partnership with The Gynecologic Oncology Group (GOG) through the Industry Collaboration Team (ICT) program.  By becoming a member of the ICT, OvaGene Oncology demonstrates its commitment to building a strong partnership with the GOG research groups, namely medical centers, universities, and pharmaceutical companies dedicated to advancing the scientific and clinical knowledge of gynecologic cancers.  

OvaGene's mission to improve the quality of life and survival for gynecologic cancer patients is further enhanced by joining this select group.  The Industry Collaboration Team has a limited membership and OvaGene is honored to have been given an opportunity to become a member. By joining the ICT program, OvaGene will gain direct access to oncology leaders and key decision makers in the field gynecologic oncology.  This will facilitate direct communication with the cancer treating physicians about OvaGene's products and diagnostic research capabilities. The valuable feedback provided can help accelerate the development of OvaGene's product pipeline by allowing the company to identify and address unmet clinical needs.

"We are very pleased to be an ICT member," said William Ricketts, Ph.D., Chief Scientific Officer for OvaGene.  "The GOG has one of the largest archived and annotated gynecologic tumor banks.  It is a privilege to be given the opportunity to collaborate with the GOG as a member of the ICT and potentially on studies focused to discover and validate new molecular diagnostics. This will help us bring clinically useful tests to market for improved patient care and outcome."  

Dr. Neil Finkler, M.D., Chief Medical Officer for OvaGene stated, "We are very enthusiastic about this collaboration. The ability to run our clinical studies on archived tissues from the GOG, as well as future prospective trials, adds an additional level of validation and scientific review to our studies that will ultimately improve the quality of our product offerings leading to improved patient care."

About OvaGene Oncology

OvaGene Oncology is a molecular diagnostics company, located in Orange County California, dedicated to improving cancer care and outcomes for gynecologic cancer patients through the development of novel gene-based assays.  The company plans to offer proprietary and non-proprietary molecular diagnostic assays to assist physicians in the prognosis of gynecologic cancers as well as therapy selection, including radiation and chemotherapy.  There are over 11,000 cases of cervical cancer, 25,000 cases of ovarian cancer and 42,000 cases of endometrial cancer diagnosed each year in the United States.  The total market for OvaGene's genomic assays is over 80,000 gynecologic cancer cases diagnosed annually. Please visit our website at for more information about our company.

About The Gynecologic Oncology Group

The Gynecologic Oncology Group ("GOG") is a national organization dedicated to clinical research in the field of gynecologic cancer. It is one of the cooperative clinical trial research groups funded by the National Cancer Institute (NCI). The purpose and mission of the GOG is to improve and expand the treatment of gynecologic cancer. These goals are met through an exchange of information on programs of study, teaching methods and research activities among gynecologic oncologists, medical oncologists, radiation oncologists, nurse oncologists, pathologists, and basic scientists.  Visit for more details.

SOURCE OvaGene Oncology Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OvaGene Oncology Opens New Innovative Gynecologic Cancer Laboratory and Research Facility
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
6. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
7. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
8. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
9. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
10. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
11. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Post Your Comments:
(Date:11/24/2015)... NEW DELHI , November 25, 2015 ... fear invoked due to repeated failure of IVF cycles. ... Rani Bhatia was totally dejected and had lost all hopes that ... the first Indian miracle child conceived after failure of ... to abroad (UK) before they decided to take one last ...
(Date:11/24/2015)... 2015  In the pharmaceutical industry, companies want to ... quickly uncover new insights, tactics and strategies that will ... --> However, organizations often find it is ... ensure that all rules and regulations are met to ... barrier to efficiently launching market research projects is the ...
(Date:11/24/2015)... 2015 --> --> ... Market by Product Type (Bone Graft, Bine Graft Substitute, Platelet ... Posterior Lumbar Interbody Fusion), End User, and Geography - Global ... valued at $1.90 Billion in 2014 and is expected to ... during the forecast period of 2015 to 2020. ...
Breaking Medicine Technology:
(Date:11/24/2015)... , ... November 24, 2015 , ... New patients who ... a referral for dental implants at her Mississauga, ON practice. Dr. Williams ... in the placement of dental implants. , Missing teeth can lead to a ...
(Date:11/24/2015)... Los Angeles, CA (PRWEB) , ... November 24, 2015 , ... ... author explored the different restrictions and variables that determine which patients are or are ... are those patients that have a BMI over 40, are more than 100 pounds ...
(Date:11/24/2015)... ... November 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t ... , FDA has long asserted that design and manufacture of Laboratory ... tests and do not meet the device regulations. , Come up short in an ...
(Date:11/24/2015)... New Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... what it deems a growing epidemic as deaths from prescription opioids in the United ... from heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the ... of a holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic ... and different way. The location is scheduled to operate through Dec. 24. , Holiday ...
Breaking Medicine News(10 mins):